Health Economics›Non-small cell lung cancer›Advanced or metastatic disease first-line therapy

Advanced or metastatic disease first-line therapy

Non-small cell lung cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	RET	R 83 725	21d	11.2 mo	—	17	R 1 423 331 PFS proxy	1
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	RET	R 83 075	21d	11.2 mo	—	17	R 1 412 272 PFS proxy	1
Cisplatin and Pemetrexed Variant #01	RET	R 1 088	21d	8.6 mo	13.1 mo	13	R 14 139 PFS proxy	5
Carboplatin and Pemetrexed N/A - secondary systemic drug	RET	R 52	21d	8.6 mo	13.3 mo	13	R 677 PFS proxy	6
Selpercatinib monotherapy Variant #01 Partial	RET	—	28d	24.8 mo	—	27	—	1

5 of 5 regimens shown